🇺🇸 FDA

Company profile · Sponsor

Rani

Rani Therapeutics Holdings

RANI · NYSE pharma SAN JOSE, CA, USA
Pipeline
7
Drugs
0
Patents
8

Quick answer

Rani (RANI) is a pharma company. headquartered in SAN JOSE, CA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RANI
Exchange NYSE
Company type pharma
Headquarters SAN JOSE, CA, USA
SEC CIK 0001856725

Pipeline (7)

Search pipeline →

  1. Berubicin hydrochloride

    Rani

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  2. A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)

    Rani

    Ulcerative colitis

    phase 1 other active

    1 trial

  3. GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).

    Rani

    Ulcerative colitis

    phase 1 other active

    1 trial

  4. RT-102 (80 μg)

    Rani

    Healthy Volunteers

    phase 1 other completed

    1 trial

  5. RT-114 is the RaniPill capsule with PG-102 for the treatment of obesity

    Rani

    Obesity

    phase 1 other active

    1 trial

  6. RaniPill capsule containing octreotide

    Rani

    Healthy Volunteers

    phase 1 other completed

    1 trial

  7. Stelara

    Rani

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Patents (8)

Search patents →

  1. US 12357555

    Self-emulsifying composition, intended for administration onto the skin, containing biosurfactant, cosurfactant and oil phase

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12268831

    Swallowable drug delivery device and methods of drug delivery

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12263325

    Device, system and methods for the oral delivery of therapeutic compounds

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12214019

    Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12201721

    Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12168692

    Antibodies targeting CCR2

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12128133

    Ingestible device with expandable enclosure

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12077551

    Zinc complex, preparation thereof and use thereof for trerapy of human and animal diseases

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Rani?

Rani (RANI) is a pharma company. headquartered in SAN JOSE, CA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Rani sponsor?

We track 7 ClinicalTrials.gov-linked programs for Rani, including Berubicin hydrochloride and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Rani company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.